Ligand Pharmaceuticals Incorporated Stock Price Prediction
| LGND Stock | USD 106.19 0.57 0.54% |
Momentum 43
Sell Extended
Oversold | Overbought |
Quarterly Earnings Growth 1.032 | EPS Estimate Next Quarter 1.336 | EPS Estimate Current Year 6.0855 | EPS Estimate Next Year 6.6525 | Wall Street Target Price 144.375 |
Using Ligand Pharmaceuticals hype-based prediction, you can estimate the value of Ligand Pharmaceuticals Incorporated from the perspective of Ligand Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Ligand Pharmaceuticals using Ligand Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Ligand using crowd psychology based on the activity and movement of Ligand Pharmaceuticals' stock price.
Ligand Pharmaceuticals Short Interest
A significant increase or decrease in Ligand Pharmaceuticals' short interest from the previous month could be a good indicator of investor sentiment towards Ligand. Short interest can provide insight into the potential direction of Ligand Pharmaceuticals stock and how bullish or bearish investors feel about the market overall.
200 Day MA 105.7487 | Short Percent 0.0556 | Short Ratio 8.49 | Shares Short Prior Month 951.5 K | 50 Day MA 113.972 |
Ligand Pharmaceuticals Hype to Price Pattern
Investor biases related to Ligand Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ligand. The trend in average sentiment can be used to explain how an investor holding Ligand can time the market purely based on public headlines and social activities around Ligand Pharmaceuticals Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Ligand Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Ligand Pharmaceuticals.
Ligand Pharmaceuticals Implied Volatility | 0.72 |
Ligand Pharmaceuticals' implied volatility exposes the market's sentiment of Ligand Pharmaceuticals Incorporated stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Ligand Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Ligand Pharmaceuticals stock will not fluctuate a lot when Ligand Pharmaceuticals' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Ligand Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Ligand because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Ligand Pharmaceuticals after-hype prediction price | USD 106.19 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Ligand contract
Based on the Rule 16, the options market is currently suggesting that Ligand Pharmaceuticals Incorporated will have an average daily up or down price movement of about 0.045% per day over the life of the 2025-05-16 option contract. With Ligand Pharmaceuticals trading at USD 106.19, that is roughly USD 0.0478 . If you think that the market is fully incorporating Ligand Pharmaceuticals' daily price movement you should consider acquiring Ligand Pharmaceuticals Incorporated options at the current volatility level of 0.72%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Ligand |
Ligand Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Ligand Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Ligand Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Ligand Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Ligand Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Ligand Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Ligand Pharmaceuticals' historical news coverage. Ligand Pharmaceuticals' after-hype downside and upside margins for the prediction period are 103.72 and 108.66, respectively. We have considered Ligand Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Ligand Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Ligand Pharmaceuticals is based on 3 months time horizon.
Ligand Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Ligand Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ligand Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Ligand Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.20 | 2.45 | 0.79 | 0.04 | 10 Events / Month | 13 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
106.19 | 106.19 | 0.00 |
|
Ligand Pharmaceuticals Hype Timeline
Ligand Pharmaceuticals is now traded for 106.19. The entity has historical hype elasticity of 0.79, and average elasticity to hype of competition of 0.04. Ligand is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is about 62.34%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is now at -0.2%. %. The volatility of related hype on Ligand Pharmaceuticals is about 1175.06%, with the expected price after the next announcement by competition of 106.23. About 98.0% of the company shares are owned by institutional investors. The book value of Ligand Pharmaceuticals was now reported as 43.47. The company has Price/Earnings To Growth (PEG) ratio of 1.53. Ligand Pharmaceuticals recorded a loss per share of 0.22. The entity last dividend was issued on the 2nd of July 2010. The firm had 1603:1000 split on the 2nd of November 2022. Given the investment horizon of 90 days the next estimated press release will be in about 10 days. Check out Ligand Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Ligand Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Ligand Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Ligand Pharmaceuticals' future price movements. Getting to know how Ligand Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Ligand Pharmaceuticals may potentially react to the hype associated with one of its peers.
Ligand Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Ligand price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Ligand using various technical indicators. When you analyze Ligand charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Ligand Pharmaceuticals Predictive Indicators
The successful prediction of Ligand Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Ligand Pharmaceuticals Incorporated, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Ligand Pharmaceuticals based on analysis of Ligand Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Ligand Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Ligand Pharmaceuticals's related companies. | 2024 | 2025 (projected) | Dividend Yield | 0.48 | 0.42 | Price To Sales Ratio | 11.73 | 9.21 |
Story Coverage note for Ligand Pharmaceuticals
The number of cover stories for Ligand Pharmaceuticals depends on current market conditions and Ligand Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Ligand Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Ligand Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Ligand Pharmaceuticals Short Properties
Ligand Pharmaceuticals' future price predictability will typically decrease when Ligand Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Ligand Pharmaceuticals Incorporated often depends not only on the future outlook of the potential Ligand Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ligand Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18.3 M | |
| Cash And Short Term Investments | 256.2 M |
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |